Our results suggest that serotonin and p21 act as a central molecular determinant of weight gain and associated metabolic alterations, and highlights the potential of targeting these molecules as a pharmacologic approach to prevent the development of obesity. The gene discussed is CDKN1A; the disease is obesity due to melanocortin 4 receptor deficiency.